File Download
  Links for fulltext
     (May Require Subscription)

Article: Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong.

TitleCost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong.
Authors
Issue Date2001
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation
Hong Kong Medical Journal, 2001, v. 7 n. 4, p. 360-368 How to Cite?
AbstractOBJECTIVE: To determine the cost-effectiveness of secondary prevention with pravastatin in Hong Kong patients with coronary heart disease and average cholesterol levels. DESIGN: Cost-effectiveness analysis based on published results of the CARE study. PATIENTS: Men and women post-myocardial infarction with average cholesterol levels. MAIN OUTCOME MEASURES: Cost-effectiveness analysis: cost per life saved, cost per fatal or non-fatal coronary event prevented, cost per procedure prevented, and cost per fatal or non-fatal stroke prevented. Cost-utility analysis: gross cost and net cost per quality-adjusted life year gained calculated using two alternative models. RESULTS: Cost per life saved or death prevented was HK$4,442,350 (non-discounted); cost per fatal or non-fatal cardiac event prevented HK$1,146,413; cost per procedure prevented HK$732,759; and cost per fatal or non-fatal stroke prevented HK$2,961,566. Net cost per quality adjusted life year gained was HK$73,218 and HK$65,280 non-discounted, respectively using the two alternative models. CONCLUSIONS: The results of this study can assist in prioritising the use of health care resources in Hong Kong but should be considered alongside the benefits and costs of alternative interventions for coronary heart disease.
Persistent Identifierhttp://hdl.handle.net/10722/53517
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 0.261

 

DC FieldValueLanguage
dc.contributor.authorChau, Jen_HK
dc.contributor.authorCheung, BMen_HK
dc.contributor.authorMcGhee, SMen_HK
dc.contributor.authorLauder, IJen_HK
dc.contributor.authorLau, CPen_HK
dc.contributor.authorKumana, CRen_HK
dc.date.accessioned2009-04-03T07:22:07Z-
dc.date.available2009-04-03T07:22:07Z-
dc.date.issued2001en_HK
dc.identifier.citationHong Kong Medical Journal, 2001, v. 7 n. 4, p. 360-368en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/53517-
dc.description.abstractOBJECTIVE: To determine the cost-effectiveness of secondary prevention with pravastatin in Hong Kong patients with coronary heart disease and average cholesterol levels. DESIGN: Cost-effectiveness analysis based on published results of the CARE study. PATIENTS: Men and women post-myocardial infarction with average cholesterol levels. MAIN OUTCOME MEASURES: Cost-effectiveness analysis: cost per life saved, cost per fatal or non-fatal coronary event prevented, cost per procedure prevented, and cost per fatal or non-fatal stroke prevented. Cost-utility analysis: gross cost and net cost per quality-adjusted life year gained calculated using two alternative models. RESULTS: Cost per life saved or death prevented was HK$4,442,350 (non-discounted); cost per fatal or non-fatal cardiac event prevented HK$1,146,413; cost per procedure prevented HK$732,759; and cost per fatal or non-fatal stroke prevented HK$2,961,566. Net cost per quality adjusted life year gained was HK$73,218 and HK$65,280 non-discounted, respectively using the two alternative models. CONCLUSIONS: The results of this study can assist in prioritising the use of health care resources in Hong Kong but should be considered alongside the benefits and costs of alternative interventions for coronary heart disease.en_HK
dc.languageengen_HK
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.htmlen_HK
dc.relation.ispartofHong Kong Medical Journalen_HK
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Medical Association.en_HK
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subject.meshHealth Care Costsen_HK
dc.subject.meshHypercholesterolemia - drug therapy - economics - prevention & controlen_HK
dc.subject.meshMyocardial Infarction - blood - diagnosis - drug therapyen_HK
dc.subject.meshPravastatin - economics - therapeutic useen_HK
dc.subject.meshQuality of Lifeen_HK
dc.titleCost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong.en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1024-2708&volume=7&issue=4&spage=360&epage=368&date=2001&atitle=Cost-effectiveness+analysis+of+applying+the+Cholesterol+and+Recurrent+Events+(CARE)+study+protocol+in+Hong+Kongen_HK
dc.identifier.emailCheung, BM:mycheung@hku.hken_HK
dc.identifier.emailMcGhee, SM:smmcghee@hkucc.hku.hken_HK
dc.identifier.authorityCheung, BM=rp01321en_HK
dc.identifier.authorityMcGhee, SM=rp00393en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid11773670-
dc.identifier.scopuseid_2-s2.0-0035756114en_HK
dc.identifier.hkuros70031-
dc.identifier.volume7en_HK
dc.identifier.issue4en_HK
dc.identifier.spage360en_HK
dc.identifier.epage368en_HK
dc.publisher.placeHong Kongen_HK
dc.identifier.scopusauthoridChau, J=36941253500en_HK
dc.identifier.scopusauthoridCheung, BM=7103294806en_HK
dc.identifier.scopusauthoridMcGhee, SM=7003288588en_HK
dc.identifier.scopusauthoridLauder, IJ=35564928000en_HK
dc.identifier.scopusauthoridLau, CP=7401968501en_HK
dc.identifier.scopusauthoridKumana, CR=7005112381en_HK
dc.identifier.issnl1024-2708-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats